3 results about "Clinical therapy" patented technology

This invention belongs to the field of biomedical technology, specifically involving the application of the MRPL41 gene / protein in the preparation of drugs for treating age-related sarcopenia. This invention is the first to demonstrate that MRPL41 is a key rate-limiting factor in the assembly of mitochondrial ribosomes in aging muscle satellite cells, establishing it as a core target for the treatment of age-related sarcopenia. Overexpression of MRPL41 can promote the assembly of mitochondrial 55S holoenzymes, improve the translation efficiency of mitochondrial-encoded proteins, repair mitochondrial dysfunction at its source, thereby promoting muscle repair, improving muscle atrophy, and achieving the treatment of age-related sarcopenia. This invention provides a precise microscopic target for the treatment of age-related sarcopenia, overcoming the limitations of existing clinical therapies (such as hormone replacement and simple nutritional supplementation) due to significant side effects and "anabolism resistance," providing a new direction for the development of innovative drugs specifically for the treatment of age-related sarcopenia, and has excellent application prospects.

The invention relates to a children hypothyroidism curative effect dynamic monitoring method and system fusing growth and development data. The method comprises the following steps: acquiring growth and development data of a target child patient and extracting key growth and development characteristics to obtain growth and development characteristic data; performing growth and development change trend analysis to obtain growth and development time sequence change trajectory data; inputting the trajectory data into a preset growth prediction model to deduce a future growth and development state to obtain growth and development prediction data; calculating a multi-dimensional deviation between the growth and development time sequence data and the prediction data to obtain growth and development deviation degree data; acquiring thyroid function test index data of the target child patient, and performing correlation analysis and curative effect grade mapping on the thyroid function test index data and the deviation degree data to obtain a curative effect monitoring result. By adopting the method, the problems that traditional monitoring lacks dynamic modeling, multi-source data association is insufficient and curative effect evaluation lags subjective can be solved, dynamic quantitative evaluation of the curative effect is realized, and a reliable basis is provided for clinical treatment adjustment.

The present disclosure generally relates to a LigoRNA system, and LigoRNA-based gene editing systems and uses thereof. Specifically, this disclosure provides novel base editing systems to achieve genomic editing at the base level, which enables broad applications in life science research and clinical therapy and / or biotechnology development. Also disclosed are polynucleotides, vectors, cells, and kits comprising components of the gene editing systems.